Nuwellis, Inc.

Stage 4 · Declining · week 33

As of Oct 22, 2026, Nuwellis is in Stage 4, the downtrend phase, now in week 33 (since Feb 27, 2026). It closed at $0.49, 99.7% below its 52-week high and below its 200-day average, which is falling.

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. More about the company

$0.49

-4.41% today

$1.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NUWE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 65w

S4 44w

S4 34w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 65w → S1 4w → S4 11w → S1 4w → S4 44w → S1 3w → S4 34w current

Total tracked: 166 weeks across 7 stage runs.

NUWE among Medical Devices132nd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…132	NUWENuwellis, Inc.	Stage 4 · wk 33	2	−42.4%

vs 52W High

-99.7%

$0.49 lo$146.65 hi

99.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 33

1w13w26w

Week 33, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-98.3%

200 DMA: $28.57 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.03x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-42.4%

-76.1%

-98.8%

YTD

-99.2%

-99.6%

Scan Membership

Breakout Watch

Latest: 2020-08-11

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 33 · Vol 0.03x

2026-10-21S4

Wk 33 · Vol 0.04x

2026-10-20S4

Wk 33 · Vol 0.01x

2026-10-19S4

Wk 33 · Vol 0.03x

2026-10-16S4

Wk 33 · Vol 0.05x

2026-10-15S4

Wk 32 · Vol 0.05x

2026-10-14S4

Wk 32 · Vol 0.14x

2026-10-13S4

Wk 32 · Vol 0.06x

2026-10-12S4

Wk 32 · Vol 0.04x

2026-10-09S4

Wk 32 · Vol 0.03x

2026-10-08S4

Wk 31 · Vol 0.03x

2026-10-07S4

Wk 31 · Vol 0.02x

Moving averages & range

50 DMA

$0.82

200 DMA

$28.57

52W High

$146.65

52W Low

$0.49

5D Low

$0.49

Resistance levels (recent highs)

20d High

$0.78

60d High

$4.45

120d High

$39.20

250d High

$146.65

Next resistance

+59.2%

to 20d High

P/E (TTM)

0.0

Forward -0.2

Dividend Yield

0.00%

P/B -0.1

Nuwellis: quick answers

What stage is Nuwellis in?

As of Oct 22, 2026, Nuwellis (NUWE) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 27, 2026 and is in week 33. What the four stages mean

Is Nuwellis in an uptrend?

No. Nuwellis is in a Stage 4 downtrend. It trades 98.3% below its 200-day average, which is falling.

How far is Nuwellis from its 52-week high?

Nuwellis closed at $0.49 on Oct 22, 2026, 99.7% below its 52-week high of $146.65. Its 52-week low is $0.49.

How has Nuwellis performed over the past year?

As of Oct 22, 2026, Nuwellis is down 99.6% over the past year and down 99.2% so far in 2026.

Which sector and industry is Nuwellis in?

Nuwellis is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.